The Long Road to Perdition
COVID19 vaccines are injected into the deltoid where they are taken up by muscle cells. The vaccine remains largely contained near the site of injection. Local muscle cells that take in the vaccine produce the spike protein and place it on the surface of the cell where it is recognized by the immune system. Vaccine that is not taken up by muscle is drained into the local lymph nodes where lymphatic cells absorb the vaccine and similarly make spike protein. The lymphatic cells are responsible for activating T and B cells, which are important steps in generating immunity.
In order to damage the endothelium of blood vessels, COVID-19 vaccines have to enter the vascular system and infect cells that circulate in the blood. Data collected by the European Medicines Agency shows that no significant amount of vaccine enters the circulation. The confinement of the expressed spike protein away from the circulatory system significant prevents it from causing damage to the vascular endothelium.
Redesigning the Spike Protein
The spike protein attaches SARS-CoV2 to cells through a receptor called ACE2. In order to fully interact, the spike protein must undergo a conformational change.
A research team lead by Dr. Barney Graham from the Vaccine Research Center at the NIH National Institute of Allergy and Infectious Diseases created an engineered form of the spike protein that is unable to make the shape change required to effectively bind to cells. The Pfizer/BioNTech, Moderna, Novavax, and Johnson&Johnson vaccines all use this inactivated spike protein, which means any spike protein that is produced by the vaccine is not able to be activated. This safety-switch limits the ability of the spike protein to bind ACE2 and limits its ability to cause damage.
https://www.science20.com/w_glen_pyle/the_thorny_problem_of_covid19_vaccines_and_spike_proteins-254373
有科學研究證明疫苗既spike protein已被deactivated, 不會對血管做成傷害。但又唔見你貼